Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE
Date Title  
Monday, July 17, 2017 Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development
Wednesday, June 21, 2017 Five Prime Therapeutics Announces Lewis T. "Rusty" Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018
Upcoming and Recent Events > MORE
Date Title  
Wednesday, June 7, 2017
11:00 AM ET
Jefferies 2017 Global Healthcare Conference
Supporting Materials
PDF View Presentation  1.9 MB   Add to Briefcase
Thursday, May 4, 2017
4:30 PM ET
Five Prime Therapeutics, Inc. 2017 Q1 Quarterly Earnings Call
Supporting Materials
PDF View Presentation 796.0 KB   Add to Briefcase
Thursday, February 23, 2017
4:30 PM ET
Five Prime Therapeutics, Inc. 2016 Q4 Quarterly Earnings Call
Supporting Materials
PDF View Presentation 696.1 KB   Add to Briefcase

FPRX (Common Stock)

Change (%)

Data as of 4:00 PM ET on Thursday, July 20, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.